Skip to content
Clinical Trials – home
Not recruiting

Bioequivalence study of cladribine 10 mg tablets in healthy adult volunteers for treatment of multiple sclerosis

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The study examines a medicine called Cladribine, which is used to treat multiple sclerosis, a disease where the immune system mistakenly attacks the protective coating of nerve fibers. Two tablet forms containing the same amount of the drug are being compared: the brand name Mavenclad® and a test version of the same medication. The purpose is to assess whether the test tablet shows bioequivalence with the brand tablet, meaning it behaves the same way in the body.

Healthy adult volunteers will receive a single dose of each tablet on separate visits, with a gap of at least one month between doses, while fasting (no food). After each dose, blood samples will be collected to measure how much of the drug enters the bloodstream and how quickly it reaches its highest level. These measurements are referred to as AUC (total exposure) and Cmax (maximum concentration), and the time taken to reach the maximum level is called tmax. The study will compare these values between the two tablets to determine if they are equivalent.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    First Dose Administration

    After enrollment, you will be instructed to fast for at least eight hours before the dosing visit. Fasting means no food or drink, except water, during this period.

    In the morning, you will swallow one 10 mg tablet of either the test product (cladribine 10 mg tablets) or the market product (Mavenclad® 10 mg tablets). The tablet is taken by mouth once, under fasting conditions.

    Blood samples will be collected at several time points after the dose to measure how much cladribine is present in your blood. These measurements help determine the drug’s overall exposure (total amount over time) and the highest concentration reached.

  2. Step 2

    Washout Period

    Following the first dose, you will wait for at least thirty days before receiving any further study medication. This washout period ensures that the drug is fully cleared from your body before the next dose.

    During this time you will not take any additional study tablets, but you may continue your normal daily activities.

  3. Step 3

    Second Dose Administration

    After the washout period, you will again fast for at least eight hours.

    You will then swallow a single 10 mg tablet of the product you did not receive in the first period (the other of the two tablets). This is also a one‑time, oral single dose under fasting conditions.

    Blood samples will be taken at the same intervals as during the first period to compare the drug levels between the two products.

  4. Step 4

    Study Completion

    After the final set of blood samples, the study is complete for you. No further medication is required.

    You may be asked to complete a brief questionnaire about any symptoms or experiences you had during the trial.

Who can join the trial?

9 criteria

  • Be a male volunteer.
  • Be between 18 and 55 years old when you sign the consent form.
  • Be physically and mentally healthy, as confirmed by a medical check‑up and routine lab tests (blood and urine tests).
  • Be a non‑smoker or have quit smoking at least 6 months ago, with a smoking history of no more than 5 pack‑year (one pack per day for one year). You must also not use any other nicotine products, and a urine test will confirm this.
  • Have a body‑mass index (BMI) between 20 and 30 kg/m². BMI is a number that compares your weight to your height.
  • Weigh at least 70 kg at the screening visit.
  • Use two reliable methods of contraception (for example, spermicidal gel plus a condom) for the whole study and for 6 months after the last dose, or have had a vasectomy performed more than 6 months before the first dose. You must also avoid donating sperm for 6 months after the last dose.
  • Be able to fast (not eat or drink anything except water) for at least 14 hours before taking the study medication and then eat normal meals afterward.
  • Sign a written informed consent form agreeing to take part in the trial.

Who cannot join the trial?

38 criteria

  • Participating in another clinical trial at the same time or within the last 90 days before the screening visit.
  • Being assigned to this study (randomized) more than once.
  • Being hospitalized for any reason within 8 weeks before receiving the study drug.
  • Planning to be hospitalized within 3 months after the last dose of the study drug.
  • Donating blood or losing more than 500 mL of blood (including plasma) within 90 days before screening.
  • Having a history of drug abuse or using illegal drugs: marijuana within 6 months, or harder drugs such as cocaine, amphetamines, or PCP within 1 year.
  • Alcohol abuse, meaning regularly drinking more than 2 units per day (about 250 mL beer, 125 mL wine, or 25 mL spirits) or 10 units per week, or having a past problem with alcoholism.
  • Regularly drinking coffee, tea, cola, chocolate or other foods that contain more than 500 mg of caffeine (a type of methylxanthine) per day.
  • Having an allergic tendency or any significant allergic disease such as asthma or severe bronchial reactivity.
  • Any history of drug hypersensitivity (allergic reaction to a medicine), especially to the active or inactive ingredients in cladribine tablets (for example, sorbitol).
  • Having a current or past serious disease of the heart (cardiovascular), kidneys, liver, lungs, metabolism, hormones, blood, digestive system, nervous system, mental health, or any other major organ system.
  • Being ill with a clinically important illness within 4 weeks before the screening visit.
  • Having a history or current infection with tuberculosis (TB), serious infections such as sepsis, or opportunistic infections.
  • Having had major surgery on the gastrointestinal (digestive) tract, except for a simple appendix removal.
  • Having any chronic disease that might affect how the drug is absorbed, distributed, broken down (metabolized) or removed from the body.
  • Following a special diet (e.g., vegetarian, low‑salt, gluten‑free, etc.) within 4 weeks before the first dose.
  • Having difficulty swallowing solid tablets.
  • Having difficulty donating blood or having veins that are hard to access for blood draws.
  • Having a history of suicidal thoughts or behavior.
  • Having a history of seizure disorders (epilepsy).
  • Taking medicines that can change major organ function (such as barbiturates, phenothiazines, cimetidine, omeprazole) within 60 days before screening.
  • Receiving depot injectable drugs or any medication with a half‑life longer than 1 week within the past 6 months.
  • Taking enzyme‑inducing, organ‑toxic, or long half‑life drugs within 4 weeks before screening.
  • Using any prescription, over‑the‑counter, or herbal medication (including pain relievers, fever reducers, antacids, St. John’s wort, kava, ginseng) within 2 weeks before screening.
  • Receiving any live or weakened (attenuated) vaccine within 4–6 weeks before screening.
  • Using drugs that inhibit or induce CYP enzymes (important for drug metabolism) within 30 days before taking the study medication.
  • Having laboratory test results that are clinically abnormal, especially white blood cells (leukocytes) or lymphocytes more than 20 % below the normal lower limit or twice above the normal upper limit.
  • Testing positive for HIV antibodies, hepatitis B surface antigen, hepatitis C antibodies, or syphilis.
  • Testing positive on the QuantiFERON‑TB Gold test (a blood test for tuberculosis).
  • Having kidney failure with a creatinine clearance less than 60 mL/min.
  • Testing positive on a urine drug screen for illegal drugs or nicotine (cotinine).
  • Having a positive breath alcohol test.
  • Having a systolic blood pressure (top number) outside 100–140 mmHg or a diastolic blood pressure (bottom number) outside 60–90 mmHg.
  • Having a resting pulse rate outside 50–100 beats per minute.
  • Having an axillary (under‑arm) body temperature outside 35.5–37.4 °C.
  • Having a respiratory rate (breaths per minute) outside 14–20.
  • Having a clinically significant abnormality on a resting 12‑lead ECG (heart electrical test).
  • Being known or suspected to be unable to follow study rules, be reliable, understand the consent information, or being in legal custody, institutional confinement, or severe financial distress that could affect decision‑making.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Mavenclad

    is a commercially available tablet that contains the medicine cladribine. In this study it is used as the reference product, meaning the researchers compare the new tablet to this known version to see if they behave the same way in the body. The tablet is taken by mouth on an empty stomach.

  • Cladribine

    is the test tablet being evaluated in the trial. It also contains the same active ingredient, cladribine, but it is a new formulation that the investigators want to check for similarity to the marketed product. Like the reference tablet, it is swallowed whole and taken while fasting.

What is already known about the treatment

  • Mavenclad

    Mavenclad is taken as a 10 mg oral tablet that is swallowed with water. It is an approved medicine used to treat adults with highly active relapsing multiple sclerosis and is widely described in medical literature. The drug works by acting as a purine‑like molecule that enters immune cells and interferes with DNA building, which reduces the number of cells that cause inflammation. It belongs to the class of immunosuppressant antimetabolites and is considered a disease‑modifying therapy for MS.

  • Cladribine

    The test product is also a 10 mg oral tablet taken by mouth with water. Cladribine is the same active ingredient as Mavenclad and is approved for the same MS indication, with many studies published on its safety and effectiveness. It works by mimicking a natural building block of DNA, entering certain immune cells and disrupting their ability to multiply, thereby lowering the immune attack on the nervous system. It is classified as an immunosuppressive antimetabolite used as a disease‑modifying treatment for multiple sclerosis.

Investigated diseases

Highly active relapsing multiple sclerosis - Multiple sclerosis is a chronic disease of the central nervous system in which the immune system attacks the protective covering of nerve fibers. In the relapsing form, symptoms appear in episodes (relapses) followed by periods of partial or complete recovery (remission). When the disease is highly active, relapses occur frequently and new lesions develop quickly, leading to a steady accumulation of disability. The condition progresses with increasing difficulty in walking, coordination, vision, and sensory function as more nerve pathways are damaged. Over time, the intervals between relapses may shorten and recovery may become less complete.
Trial detailsLast updated 18 Nov 2026
Age18+ yearsPhasePhase ITrial ID2023-508656-19-00Protocol codeCPO23001Estimated enrolment76 patientsSponsorCCDRD Cooperative Clinical Drug Research and Development AG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.